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periodontitis is an economically important disease which is highly prevalent worldwide. current 
diagnostic approaches are time-consuming and require interpretation of multiple aspects of clinical 
and radiographic assessment. Chair-side monitoring of inflammatory mediators of periodontitis could 
provide immediate information about disease activity, which can inform patient management. We 
aimed to develop a novel prototype biosensor to measure salivary matrix metalloproteinase-8 (MMP-8) 
using specific antibodies and surface acoustic wave (SAW) technology. The analytical performance of 
the prototype biosensor was compared to standard enzyme-linked immunosorbent assay (ELISA) using 
unstimulated saliva samples obtained from patients with periodontitis before and after non-surgical 
treatment (N = 58), patients with gingivitis (N = 54) and periodontally healthy volunteers (N = 65). 
Receiver operator characteristic (ROC) analysis for distinguishing periodontitis from health revealed 
an almost identical performance between the sensor and ELISA assays (area under curve values (AUC): 
ELISA 0.93; SAW 0.89). Furthermore, both analytical approaches yielded readouts which distinguished 
between heath, gingivitis and periodontitis, correlated identically with clinical measures of periodontal 
disease and recorded similar post-treatment decreases in salivary MMP-8 in periodontitis. The assay 
time for our prototype device is 20 minutes. The prototype SAW biosensor is a novel and rapid method 
of monitoring periodontitis which delivers similar analytical performance to conventional laboratory 
assays.
Periodontitis is a chronic inflammatory disease that affects the supporting structures of the teeth, leading to tooth 
mobility and early tooth loss, that has significant impacts on oral function and quality of life. It is an economically 
important disease that is associated with a number of systemic diseases, and advanced periodontitis has been 
identified as the 6th most common disease to affect mankind1. Early diagnosis of periodontitis enables earlier 
and more effective intervention and better long term prognosis in addition to facilitating minimally invasive and 
less time consuming therapies which are more acceptable for patients as well as being economically efficacious.
Current practices for the management of periodontitis are based on interpretation of clinical and radiographic 
observations rather than objective analysis of the biological factors underlying the disease pathogenesis2,3. These 
procedures are time consuming, require skilled clinicians and are expensive. There is a strong economic prerog-
ative to deliver improved periodontal healthcare in the face of increasing disease prevalence worldwide4–6. The 
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increasing appreciation of the clear association of poor periodontal health with common chronic diseases such 
as cardiovascular disease and diabetes in the wider medical community has highlighted the need for effective 
diagnostic tests for periodontitis to inform preventative approaches5.
Periodontitis tends to proceed in an episodic fashion, with periods of tissue destruction followed by quiescent 
phases, which may correspond to periods of repair2,3. Currently, the tissue breakdown that characterises perio-
dontitis is determined using periodontal probes and radiographs. However, there is a requirement for diagnostic 
approaches above and beyond traditional approaches based on understanding of the underlying pathogenesis7. 
Such ‘evidence-based knowledge’ is considered critical in preventing clinical mismanagement through the appli-
cation of inappropriate treatment and failure to correctly characterise active disease8.
There is interest in identifying potential biomarkers of periodontitis in oral fluids and investigating their util-
ity in periodontitis diagnosis and longitudinal disease monitoring9–12. Saliva is a convenient sampling medium 
for oral diseases as it is abundant and easily accessible through painless and non-invasive procedures, which do 
not require sophisticated clinical training to perform10,13. The salivary biomarkers, which show most promise in 
terms of independent replicative studies of disease discrimination and clinical association, have been found to 
be monocyte-and neutrophil-derived enzymes and, in particular, MMP-810,12,14. Numerous studies confirm that 
MMP-8 in oral biofluids (and in particular gingival crevicular fluid, GCF) is quantitatively associated with clinical 
measures of periodontitis both cross-sectionally and longitudinally during treatment9,10,12. MMP-8 levels reflect 
progression of periodontitis and successful treatment and, as such, MMP-8 assays may have positive predictive 
value for periodontal disease progression14–17.
Despite the fact that substantial data endorse the potential of mediators such as MMP-8 as biomarkers of per-
iodontitis, there remains the need to translate this knowledge into so-called ‘high impact diagnostics’ which can 
significantly uplift clinical decision-making, patient outcomes and oral (and general medical) healthcare econom-
ics18. Development of point-of-care (POC) devices for the dental clinic are especially attractive as they provide 
immediate (and objective) information to support patient management and are potentially transferrable to other 
environments such as the home, the care-home, and ‘in the field’ in areas where clinical facilities are not available.
The fundamental requirements for diagnostic tests for periodontitis have been defined19 but, clearly, new diag-
nostic approaches will need to be fit for clinical purpose in terms of analytical performance before ergonomics 
and economic factors are considered. Several analytical platforms to measure MMP-8 have been proposed to have 
utility as POC devices for periodontitis12,17. Some approaches rely on the collection of GCF12, a procedure which 
requires considerable clinical expertise and is fraught with technical challenges in terms of quantification of solu-
ble mediators20. It is well documented that saliva collection is more convenient and acceptable to the patient and, 
furthermore, salivary mediators are reflective of biological processes in the whole mouth rather than at individual 
periodontal sites (as with GCF)10.
The only currently marketed POC device for salivary molecular biomarker analysis is the Periosafe® test 
which combines lateral flow technology with ELISA detection chemistry to detect active MMP-8 (aMMP-8) in 
mouth rinse samples17,21. Other prototype POC tests which measure neutrophil elastase (MMP-9) in GCF and 
salivary C-reactive protein have been described but information on their clinical utility is, thus far, limited22.
Also, tests based on the detection of neutrophil aspartate aminotransferases in GCF have been described, 
although these tests are compromised by complex sample processing steps and unsatisfactory correlation of read-
outs with clinical periodontal parameters23,24. Other platforms for multiplex analysis of soluble mediators includ-
ing cytokines and MMPs have been outlined in preliminary reports which remain to be followed by substantial 
analytical or clinical performance data25–27.
The prototype biosensor we describe herein captures MMP-8 using specific antibodies coated on a small 
biochip, and quantifies salivary MMP-8 via microelectromechanical piezoelectric SAW technology28,29. The bio-
sensor provides a quantitative readout proportional to levels of salivary MMP-8. Furthermore, the biosensor 
assay exhibits an analytical performance comparable to that of ‘gold standard’ ELISA assays for MMP-8, shows 
significant correlation with conventional clinical parameters of periodontitis, clearly distinguishes between peri-
odontitis and gingivitis, and tracks MMP-8 changes after clinical treatment.
Results
Analytical characteristics of the biosensor assay of MMP-8. The dose-response performance for 
analysis of human recombinant MMP-8 (hrMMP-8, Biotechne) in buffer is illustrated in Fig. 1. The effective 
range for this assay is 0–1000 ng MMP-8/ml with an estimated limit of detection of 62.5 ng/ml. Although the limit 
of detection is not the same as ELISA30, the biosensor performed as well as the ELISA in the clinically relevant 
range (Fig. 1a). To assess the reproducibility of the SAW biosensor assay, 3 saliva samples with range of different 
MMP-8 levels were analysed by the biosensor in quadruplicate in one assay (intra-assay variation) on the same 
biochip and one saliva sample tested in quadruplicate on 3 consecutive days (inter-assay variation) on separate 
biochips; these experiments provided both intra- and inter-assay variation of 13.2% which is slightly higher than 
similar data for the Quantikine ELISAs (8% for both inter- and intra-assay)30. In a later iteration of the analysis 
protocol, direct binding of capture antibody anti-MMP-8 to sensor chip (omitting the anti-Ig antibody) reduced 
assay time and improved reproducibility with no effect on performance. Thus, biochips were used in the following 
protocol: incubation with 20 μl TBS-T for 1 minute, 20 μl of sample containing MMP-8 (standard or saliva) was 
then added for 5 minutes followed by 5 x TBS-T for 2 minutes, secondary anti-MMP8 antibody for 5 minutes 
followed by a 1 minute wash with 5 x TBS-T. This protocol yielded similar standard curves (not shown) but with 
reduced assay time (15 minutes) and improved reproducibility (8.6% and 9.1% intra-assay and inter-assay varia-
bility respectively).
Comparative analysis of salivary MMP-8 by ELISA and biosensor methods. Analysis using both 
the ELISA and the new MMP8 biosensor indicated that the levels of salivary MMP-8 were significantly different 
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(P < 0.001) between healthy volunteers, patients with untreated gingivitis and patients with untreated periodon-
titis (Fig. 2a,b). Furthermore, there was a statistically significant correlation between the analytical readouts for 
both assays (Fig. 2c). The broad range of values for MMP-8 levels reflects the unbiased inclusion of values from 
the analysis of samples from all 3 clinical groups. ROC analysis revealed that both ELISA and sensor analysis for 
Figure 1. Response of the biosensor to hrMMP-8. Biosensor phase change response to increasing 
concentrations of hrMMP-8 (0–1000 ng/ml). Overlaid plots of raw data from a single experiment showing phase 
shifts recorded as a function of time after the addition of the detection antibody at t = 0 (a). Graph illustrating 
the relationship of relative phase change between samples containing MMP-8 and controls (Δϕ) (b). Phase 
change measurements were made after final buffer wash (see Methods). Data are derived from 3 independent 
experiments each comprising parallel duplicate measurements on separate microchips and are presented as 
means ± SD (n = 6).
Figure 2. Analytical performance of the biosensor for the assay of salivary MMP-8 in periodontal disease. 
Analysis of salivary MMP-8 in healthy volunteers (N = 56), patients with gingivitis (N = 47) and patients with 
periodontitis (n = 65) using ELISA (a) and the biosensor assay (b). Data are means of duplicate measurements 
and are presented as box and whisker plots: boxes represent median (line) and interquartile ranges and whiskers 
the minimum and maximum range. Data was analysed using Kruskal-Wallis one-way ANOVA with Mann-
Whitney U post hoc test, *P < 0.001. Correlation of salivary MMP-8 analysis of clinical samples (n = 168) using 
ELISA and biosensor assays (c). Data were analysed using Spearman’s Rank correlation, Rho = 0.795, P < 0.001.
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salivary MMP-8 provided similar sensitivity and specificity in terms of distinguishing MMP-8 levels in healthy 
individuals from those in both gingivitis patients (Fig. 3a) and periodontitis patients (Fig. 3b).
Analysis of MMP-8 in relation to disease severity and treatment. Salivary MMP-8 measurements 
using both analytical methods correlated similarly with clinical measures of periodontitis taken at the beginning 
of study (Table 1). Thus, there were significant correlations between salivary MMP-8 levels as measured by the 
biosensor and ELISA methods and bleeding on probing (BOP) (P = 0.022 and P = 0.005 respectively), perio-
dontal probing pocket depth (PPD) (P = 0.001 and P = 0.002 respectively), periodontal inflamed surface area 
(PISA) (both P = 0.003), and periodontal epithelium surface area (PESA) (P = 0.001 and P = 0.004 respectively), 
but not mean gingival index (MGI) (P = 0.0228 and P = 0.272 respectively), or clinical attachment loss (CAL) 
(P = 0.734 and P = 0.092 respectively), (Table 1). The strength of correlations between the clinical measurements 
and MMP-8 were similar using both the ELISA and the biosensor assays (Table 1). We also tested the ability of 
the biosensor assay to measure changes in MMP-8 6 months after the commencement of non-surgical treatment 
for periodontitis. In agreement with the literature, ELISA measurements of MMP-8 before and after treatment 
in 62 paired pre-treatment and post-treatment samples demonstrated a significant reduction in salivary MMP-8 
levels (P < 0.001, Supplemental Fig. 1). We then assayed MMP-8 in saliva taken from a sub-group (n = 20) of 
periodontitis patients using the biosensor assay and recorded a similarly significant reduction in posttreatment 
MMP-8 levels in the group as a whole (P = 0.026, Fig. 4a). It is worthy of note that MMP-8 levels did not decline 
post-treatment in a minority of patients in this cohort (Fig. 4b).
Prototype interleukin-1β (IL-1β) sensor. In preliminary experiments we have extended our experi-
mental approach to develop a biosensor to measure salivary IL-1β which is similarly sensitive and reproducible 
(Supplemental Fig. 2a). Also, the prototype IL-1β sensor provides measurements which correlate with those 
derived from ELISA measurements (Supplemental Fig. 2b).
Discussion
The aim of the present study was to develop a novel prototype biosensor to measure salivary MMP-8 using spe-
cific antibodies and SAW technology. We selected MMP-8 because of its known role in the pathogenesis of per-
iodontal disease and a substantial literature supporting its role as a biomarker of gingivitis and periodontitis. 
Using ELISA we confirmed the utility of MMP-8 measurements using the biosensor in distinguishing periodontal 
Figure 3. Diagnostic performance of salivary MMP-8 analysis using the biosensor and ELISA in periodontal 
disease. Comparative receiver operator characteristic (ROC) plots for salivary MMP-8 measurements using 
ELISA and the biosensor assay (BS) assays. Sensitivity and specificity of gingivitis diagnosis (vs health) (a) and 
periodontitis diagnosis (vs health) (b) are presented and AUC data and P values included.
Clinical periodontal measurement
Assay for MMP-8
Biosensor phase change ELISA
Spearman’s rho P Spearman’s rho P
Bleeding on probing (BOP) 0.287 0.022 0.347 0.005
Mean gingival index (MGI) 0.153 0.228 0.139 0.272
Probing pocket depth (PPD) 0.403 0.001 0.382 0.002
Clinical attachment loss (CAL) 0.043 0.734 0.212 0.092
Periodontal inflamed surface area (PISA) 0.367 0.003 0.369 0.003
Periodontal epithelial surface area (PESA) 0.391 0.001 0.359 0.004
Table 1. Correlation of salivary MMP-8 assays with clinical parameters of periodontitis as assessed in untreated 
periodontitis patients (N = 65).
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health from gingivitis and periodontitis, the quantitative association of salivary MMP-8 levels with severity of 
periodontitis and the association of reduced levels with clinical improvement after non-surgical treatment for 
this disorder. These data are comparable to previously reported data for the analysis of MMP-8 in saliva collected 
by passive drooling15,31–33. We successfully developed a protocol for the construction and operation of a prototype 
biosensor to measure total MMP-8 in human saliva. The analytical performance of the biosensor in terms of sen-
sitivity and reproducibility of MMP-8 analysis compared favourably to that of the commercial ELISA kit and the 
data in terms of clinical association of measured MMP-8 was almost identical. We did identify some 7 periodon-
titis patients with MMP-8 levels >2000 pg/ml which are outwith the range of data we recorded for other patients 
but within the range recorded in a meta analysis of other studies of salivary MMP-8 levels34. The wide range of 
inter-subject variability in salivary MMP-8 levels may be clinically relevant and may be useful in developing novel 
paradigms for biomarker analysis in periodontitis which may extend their clinical utility12,35.
The biosensor has the advantage of real-time measurements, and modification of protocols for chip prepa-
ration and washing allowed the reduction in time of analysis to approximately 15 minutes. Also, unlike many 
lateral flow-type sensors, the sensor system has a scalable readout rather than relying on the appearance of col-
ours or bands. Clearly, as previously outlined28, there are aspects of the biosensor that currently limit the utility 
of this device. Activation of biochip is a procedure which is carried out by manual steps which may influence 
chip-to-chip reproducibility; this can be improved by using automated inkjet printing which also facilitates mass 
production28,29. There are multiple assay steps which require manual pipetting; in our development work, we have 
addressed this by omitting an antibody binding step which has reduced assay time and developments are already 
underway to incorporate all components into an integrated reaction cassette, during mass manufacture, which 
allows for simple one-step sample addition and subsequent read-out. The cassette also incorporates developments 
in microfluidics that facilitate sample mixing without multiple pipetting steps36. Also, the laboratory prototype 
biosensor described herein currently employs simultaneous duplicate measurements using 2 biochips; use of a 
reference biochip28 or even a dual channel biochip with an in situ reference29 reduces the effects of both inter-chip 
variation and non-specific effects such as temperature and sample viscosity variation. There are opportunities to 
develop a more streamlined sample collection regimen, for example, collecting a mouth rinse rather than saliva 
by passive drooling and filtration of oral fluid through syringes rather than centrifugation as has been employed 
with other POC devices21.
There are several other point-of-care devices designed to aid periodontal disease management which have 
been reported in the literature. The Periosafe® test combines lateral flow technology with ELISA detection chem-
istry to detect active MMP8 (aMMP-8) in mouth rinse samples17,21,37,38. The ‘readout’ comprises the appearance 
of lines of varying intensity: a light line indicates low ‘risk’ and a dark line high ‘risk’37. The test has a limit of 
detection of 20–25 ng/ml aMMP-8. The results of analysis using this kit correlated with poor oral hygiene, perio-
dontitis and BOP38 and has an overall sensitivity of 76–90% and specificity of 96% in the diagnosis of periodon-
titis although there are no data for gingivitis21,37–39. The Periosafe® test also gives readouts which correlate with 
quantitative reductions in MMP-8 levels post-treatment17. The Periosafe® test employs a proprietary antibody 
to aMMP-8 and therefore only assays the enzymatically active fraction of total MMP-8. The biosensor, like the 
ELISA kit used in this study (Quantikine, R&D Systems), employs antibodies to total MMP-8 (which includes the 
inactive pro-MMP-8 fraction). However, the analytical and clinical performance characteristics of the Periosafe® 
test are similar to the biosensor assay platform described herein. Other research recording the utility of salivary 
MMP-8 assays in diagnosis of periodontitis has likewise employed assays using antibodies to total MMP-8 in 
ELISA assays15,33.
Figure 4. Comparative biosensor analysis of salivary MMP-8 before and after treatment for periodontitis. 
Analysis of salivary MMP-8 in a sub-group of patients (n = 20) before and after 6 months after non-surgical 
treatment for periodontitis. (a) Data presented as ‘box and whisker plots’: boxes represent median (line) and 
interquartile ranges and whiskers the minimum and maximum range. Data were analysed using a paired 
samples t-test *P = 0.026. (b) Figure showing the changes in levels on MMP-8 before and after treatment in 
saliva samples from individual patients.
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It is possible that assay of oral MMP-8 (in the form of GCF, saliva or oral rinse) has positive predictive value for 
clinical outcome in periodontitis. The ELISA and biosensor assays both recorded a significant reduction in sali-
vary MMP-8 after periodontitis treatment in the group as a whole. Although, in agreement with other studies 14,15, 
we noted some inter-individual variability in the longitudinal changes in MMP-8 levels post-treatment14,15. A 
reduction in levels of MMP-8 in oral fluids (principally GCF) is associated with successful treatment for perio-
dontitis12. A recent study using both the Periosafe® test and an immunoassay revealed a remarkably consistent 
reduction of aMMP-8 as measured in oral rinse samples 6 weeks post-treatment in 10 patients17. Clearly, more 
substantial, longitudinal clinical studies of salivary biomarkers in periodontitis are warranted before their clinical 
utility, and that of POC devices including the prototype sensor described herein, which analyse them, can be 
determined17.
It is recognised that other salivary biomarkers (e.g. MMP-9, IL-1β) may be clinically useful either when meas-
ured in isolation or in combination with other candidate biomarkers such as MMP-812,15,31–33,40. The prototype 
biosensor system we have developed employs a simple capture and detection dual antibody system and is adapt-
able to the assays of other analytes. Indeed, we have developed similar biosensor assays for IL-1β (Supplementary 
data). This opens up the possibility of developing sensors based on simultaneous multiplex analysis for different 
analytes. We also note that assay of biomarkers in oral fluids has potential application to the clinical monitoring 
of other oral inflammatory conditions such as peri-implantitis21.
The current research is based on biochips in a laboratory prototype sensor; for commercial development 
the biochip will be packaged in a disposable cassette which can send data to a smartphone via Bluetooth; the 
potential physical and functional characteristics of such a portable hand-held device have been outlined in detail 
elsewhere28,29. In line with other POC devices, the speed of the test will support patients, carers and health-care 
professionals by widening access to objective clinical measurements outside the clinical setting41. This will be 
particularly important given the high prevalence of periodontitis and the increasing recognition of the clinical 
relationship between periodontitis and a number of common chronic conditions including, in particular, diabetes 
and cardiovascular disease.
Materials and Methods
Prototype sensor for MMP-8. The prototype sensor comprises a disposable SAW biochip functionalised 
with specific antibodies which delivers an analogue signal to a control box upon analyte detection. The control 
box converts the signal to a digital format which is received by a laptop PC with dedicated software to process 
the signal. The physical structure and microelectronic architecture of the biochips used in the sensor have been 
described previously28,42. Briefly, the biochip comprises interdigitating input and output gold electrodes linked by 
a gold film coated sensing area built on a plane piezoelectric quartz crystal. This structure facilitates excitation of 
a shear horizontal SAW of defined wavelength and frequency. The biosensor has a protective glass covering and 
epoxy walls constructed as previously described42.
Capture antibodies on the surface of the gold film and this biochip thereby become sensitive to reactions (e.g. 
antigen binding) by means of a SAW velocity and /or amplitude changes due to surface condition changes28,42. 
Thus, upon application of a biological fluid containing antigen (e.g. MMP-8) the mass and/or viscosity pertur-
bation caused by antigen/antibody binding is detected by the difference in wave phases between the input and 
output electrodes (i.e. phase change, Δϕ).
Biochip functionalization. The architecture of functionalised biochip and the antibody/analyte interac-
tions are illustrated in Fig. 5. Anti-Ig antibodies (polyclonal anti-mouse Fc, Jackson ImmunoResearch Europe Ltd, 
Ely, UK) were used to bind an analyte-specific primary antibody. This primary antibody subsequently captures 
the analyte, the presence of which is detected when the secondary antibody binds the immobilised immune 
complex. The antibodies used were: human MMP-8 capture antibody (mouse monoclonal, MAB908, Biotechne, 
Abingdon, UK), human MMP-8 detection antibody (goat polyclonal, AF908, Biotechne). The functionalisation 
protocol for the biochips was as follows: the SAW biochips were cleaned in a 2% (v/v) solution of Hellmanex 
III (Hellma Analytics, Southend, UK) followed by copious washings with deionized water. Biochips were acti-
vated by incubation with a 4 mg/ml solution of dithiobis [succinidyl propionate] (DSP, Thermo Fisher Scientific, 
Loughbourgh, UK) in DMSO (Thermo Fisher Scientific) followed by washes with DMSO and PBS. Subsequently 
the biochips were functionalised by incubation of 100 μg/ml anti-Ig antibody in PBS followed by a PBS wash. 
Unreacted DSP was inactivated by successive washing with TBS-T buffer (Tris-buffered saline at pH7.6 with 
0.05% v/v Tween 20). The surface was incubated with 2% (w/v) bovine serum albumin (BSA, Sigma Aldrich, 
Gillingham, UK) to block non-specific binding.
testing protocol. The biochips were placed in a receptacle on a laboratory prototype biosensor device con-
nected to a control box for data logging and transmission to laptop for processing. This can simultaneously read 
the phase changes from two biochips independently. The output data were, therefore, the mean of 2 simultaneous 
measurements of the same sample. A stable buffer baseline was established with 20 μl TBS-T. The testing pro-
tocol comprised successive incubations with 20 μl of reagents as follows: TBS-T for I minute, 100 mM HCl for 
2 minutes, wash with 5 volumes of TBS-T for 2 minutes, anti-MMP-8 capture antibody (30 μg/ml) for 5 minutes, 
wash 5 x with TBS-T for 2 minutes, sample for 5 minutes, TBS-T wash 5x for 2 minutes, anti-MMP-8 detection 
antibody (30 μg/ml) for 5 minutes, wash 5x with TBS-T to get a final reading. The surface was regenerated with 
100 mM HCl and finally washed 5x with TBS-T. Note that the protocol was optimised during the study (see 
Results section).
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eLiSA. Salivary MMP-8 was measured using ELISA (Quantikine, Biotechne) according to the manufactur-
er’s instructions. Samples were analysed in duplicate, absorbance read at 450 nm on a FL600 Microplate Reader 
(Biotek, Swindon, UK) and MMP-8 concentrations calculated from standards by means of a 4-parameter logistic 
curve fit using the proprietary software (KC4 KinetCalc, Biotek).
clinical samples. Three subject groups were recruited as part of this study: periodontally healthy volunteers 
(N = 56), patients with gingivitis (N = 47), and patients with chronic periodontitis (N = 65). All participants were 
adult males or females aged between 18 and 65 with a minimum of 20 natural teeth (excluding 3rd molars) and 
were non-smokers. The diagnostic criteria were as follows: healthy participants had PPD of ≤ 3 mm in all sites, 
no sites with interproximal attachment loss, MGI scores of ≥ 2.0 in ≤ 10% of sites and %BOP scores of ≤ 10%; 
gingivitis patients had MGI of ≥ 3.0 in ≥ 30% of sites, no sites with interproximal attachment loss, PPD > 4 mm 
and %BOP scores of ≥ 10%; periodontitis patients had interproximal PPD of ≥ 5 mm at ≥ 8 teeth and % BOP 
scores of ≥ 30%. All subjects provided written informed consent, the study was conducted at the Dental Clinical 
Research Facility of Newcastle Dental Hospital (part of the Newcastle upon Tyne Hospitals NHS Foundation 
Trust) and the study was fully approved by the National Research Ethics Service North East Newcastle and North 
Tyneside 1 committee (Ref: 12/NE/0396). All methods were performed in accordance with relevant guidelines 
and regulations. Subjects with evidence of infectious or systemic disease, currently undergoing treatment with 
antibiotics or immunosuppressants or those who had smoked within the last 2 years were excluded from the 
study. Full mouth periodontal clinical indices were recorded, and saliva samples were collected at month 0 (all 
subjects) as well as 3 months post-treatment (gingivitis and periodontitis patients), and 6 months (periodontitis 
patients). Periodontal clinical indices were recorded at 6 sites per tooth and included GI, PPD, gingival reces-
sion, CAL and % BOP. PISA and PESA were calculated as previously published43. Unstimulated saliva samples 
(3–5 ml) were collected by expectoration into a plastic centrifuge tube, placed on ice immediately after collection 
and centrifuged for 15 minutes at 1500 g and at 4 °C. Aliquots were frozen in liquid nitrogen and stored at −80 °C 
until analysis. PISA and PESA were calculated as previously published43. Unstimulated saliva samples (3–5 ml) 
were collected by expectoration into a plastic centrifuge tube, placed on ice immediately after collection and cen-
trifuged for 15 minutes at 1500 g and at 4 °C. Aliquots were frozen in liquid nitrogen and stored at −80 oC until 
analysis.
Statistical analysis. Differences in MMP-8 levels between patient groups were determined by 
Kruskal-Wallis one-way ANOVA with Mann-Whitney U post hoc tests with adjustment of the critical value of 
P as appropriate. Correlations between MMP-8 levels measured by ELISA and the sensor as well as with clinical 
parameters were carried out using Spearman’s Rank correlation. Specificity and sensitivity of analyte measure-
ments in the detection of periodontal diseases were determined by ROC analysis. Differences in phase shift results 
between pre-treatment and post-treatment periodontitis saliva samples were determined using paired samples 
t-tests. All statistical analyses were carried out using SPSS version 24.0.0 (IBM, Portsmouth, UK). P values of 
<0.05 were considered statistically significant.
Figure 5. Molecular interactions at the surface of the biosensor biochip. Schematic illustrating the 
functionalisation of the gold-coated biochip with firstly anti-IgG antibodies (red), and secondly with anti-
MMP-8 capture antibodies (blue), followed by detection by successive addition of sample (containing MMP-8) 
and anti-MMP-8 detection antibody (green). The binding of the anti-MMP-8 detection antibody to MMP-8 
bound to the immobilised complex results in a perturbation of mass at the biochip surface sufficient to generate 
a phase change (Δϕ) in the surface acoustic wave detected by the biosensor control box. In later experiments, 
the anti-MMP-8 capture antibody was bound directly to the biochip, omitting the anti-IgG antibody step. A 
full description of the prototype biosensor structure, microelectronics and detection system has been recently 
published28.
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Data Availability
The database used in this study includes clinical and laboratory data collected prospectively from consented 
volunteers and patients. This database contains protected health information and, in accordance with the ethical 
approval, has not been made publicly available.
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